

IN THE CLAIMS:

Please delete the paragraph heading on page 40 of the English translation of the amended claims according to PCT Rule 66.4, and insert in place thereof the paragraph heading as follows:

--CLAIMS--

Please insert the paragraph heading on page 40 of the English translation of the amended claims according to PCT Rule 66.4, before claim 1, the following:

-- What is claimed is: --.

Please amend claims 3 and 6-15 as follows:

3. (Amended) Method according to claim 2 wherein the eukaryotic cell is a tumor cell or a cell infected by a microorganism.
6. (Amended) Method according to claim 1 wherein the negative strand RNAs derived from the cDNA or the DNA of the gene library are introduced into one or more segments of the modified influenza viruses and/or as an additional segment into the modified influenza viruses.
7. (Amended) Method according to claim 1 wherein the modified influenza viruses are modified influenza A viruses.
8. (Amended) Method according to claim 6 wherein the preparation of negative strand RNA is performed by transcription of the pseudoviral gene segments with RNA polymerase I.
9. (Amended) Method according to claim 1 wherein following step (b), by means of selection a concentration of the recombinant virus particles is performed and/or the recombinant virus particles are isolated.
10. (Amended) Method according to claim 1 wherein after introducing the cDNA or the DNA of the gene library a superinfection is carried out using wild type influenza virus.
11. (Amended) Method according to claim 1 wherein immortalization of the antigen-presenting cells is carried out using EBV genes or oncogenes.
12. (Amended) Method according to claim 1 wherein B cells or dendritic cells are used as the antigen-presenting cells.
13. (Amended) Method according to claim 1 wherein the cleavage products of the proteins are presented on the B cell in a complex with MHC class I or MHC class II.
14. (Amended) Method according to claim 1 or 13 wherein co-cultivation of the B cells is performed with T helper cells in the case of MHC class II-restricted antigens and with cytotoxic T cells in the case of MHC class I-restricted antigens.
15. (Amended) Method according to claim 1 wherein stimulation of the antigen-specific T cells is measured by cytokine release, by T cell proliferation, or by detection of the cytotoxic activity of the T cells.

Please cancel claim 17.